Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma

Ferrari, Andrea; Miceli, Rosalba; Meazza, Cristina; Casanova, Michela; Favini, Francesca; Morosi, Carlo; Trecate, Giovanna; Marchianò, Alfonso; Luksch, Roberto; Cefalo, Graziella; Terenziani, Monica; Spreafico, Filippo; Polastri, Daniela; Podda, Marta; Catania, Serena; Schiavello, Elisabetta; Giannatempo, Patrizia; Gandola, Lorenza; Massimino, Maura; Mariani, Luigi

doi:10.1200/jco.2009.25.0803

Cited by 66 publications

(75 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A follow-up study reviewing the same cohort at end of therapy found that complete resolution status does not correlate with improved clinical outcome compared to patients with partial response or no radiographic response to therapy [22••]. It should be pointed out that a recent Italian group study did find a correlation between improved clinical outcome and measurable radiographic tumor response, using either two-dimensional or three-dimensional measurements [23]; however, this was a smaller and more heterogeneous cohort of RMS patients.…”

Section: Improving Risk Stratificationmentioning

confidence: 96%

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Huh

Skapek

2010

Curr Oncol Rep

View full text Add to dashboard Cite

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. The two most common histologic variants are the embryonal and alveolar subtypes. Although successive collaborative group clinical trials have improved survival rates for many RMS patients, the outcome for those patients with metastatic or recurrent disease remains poor. Recent studies have pointed to a possible mesenchymal stem cell as the progenitor for alveolar RMS. Other studies have implicated several cellular mechanisms and pathways being involved in RMS pathogenesis and survival, such as the cyclin-dependent kinase inhibitors, insulin-like growth factor pathway, and the mammalian target of rapamycin pathway, thus providing potential avenues for targeted therapy. Recent clinical trials have tried to improve risk stratification and prediction of clinical outcome based upon clinical or radiographic response to initial therapy and also to determine the role of high-dose chemotherapy with stem cell rescue in high-risk RMS patients.

show abstract

Section: Improving Risk Stratificationmentioning

confidence: 96%

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Huh

Skapek

2010

Curr Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Two studies showed that use of volume in assessment of response to initial therapy did not more accurately predict outcome than did use of single dimension measurements. 11,12 In children with neuroblastoma, Yoo et al 13 evaluated the relationship between primary tumor response and outcome, but did not compare methods of response assessment. Our study, to our knowledge, is the first to compare reduction in volume versus reduction in longest diameter as response measures in children with neuroblastoma.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study

Bagatell

McHugh

Naranjo

et al. 2016

JCO

View full text Add to dashboard Cite

Listen to the podcast by Dr Irwin at www.jco.org/podcastsThe International Neuroblastoma Response Criteria (INRC) require serial measurements of primary tumors in three dimensions, whereas the Response Evaluation Criteria in Solid Tumors (RECIST) require measurement in one dimension. This study was conducted to identify the preferred method of primary tumor response assessment for use in revised INRC. Patients and MethodsPatients younger than 20 years with high-risk neuroblastoma were eligible if they were diagnosed between 2000 and 2012 and if three primary tumor measurements (antero-posterior, width, craniocaudal) were recorded at least twice before resection. Responses were defined as $ 30% reduction in longest dimension as per RECIST, $ 50% reduction in volume as per INRC, or $ 65% reduction in volume.Results Three-year event-free survival for all patients (N = 229) was 44% and overall survival was 58%. The sensitivity of both volume response measures (ability to detect responses in patients who survived) exceeded the sensitivity of the single dimension measure, but the specificity of all response measures (ability to identify lack of response in patients who later died) was low. In multivariable analyses, none of the response measures studied was predictive of outcome, and none was predictive of the extent of resection. ConclusionNone of the methods of primary tumor response assessment was predictive of outcome. Measurement of three dimensions followed by calculation of resultant volume is more complex than measurement of a single dimension. Primary tumor response in children with high-risk neuroblastoma should therefore be evaluated in accordance with RECIST criteria, using the single longest dimension.

show abstract

“…Patients with the same stage of disease even showed a big discrepancy in survival. Molecules involved in cancer relapse and prognosis might serve as markers for early detection of metastasis and as a measure for therapeutic intervention (26)(27)(28)(29)(30).…”

Section: Discussionmentioning

confidence: 99%

Prediction of Colorectal Cancer Relapse and Prognosis by Tissue mRNA Levels of NDRG2

Chu

Zhang

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

NDRG2 (N-Myc downstream-regulated gene 2) is aberrantly expressed in colorectal cancer (CRC) and related to tumor differentiation status. In the present study, we investigated the association between NDRG2 mRNA levels in primary CRC to determine whether levels of NDRG2 mRNA could predict relapse and survival. A hospital-based study cohort of 226 CRC patients was involved in the study. NDRG2 mRNA levels were determined by real-time PCR. Correlations of NDRG2 mRNA expression with tumor clinicopathologic features, disease-free survival, and overall survival of the patients were studied. Significant decreased expression of NDRG2 mRNA was detected in tumor specimens. NDRG2 mRNA expression significantly correlated with differentiation status (P < 0.001), lymph node metastasis (P < 0.001), and tumor node metastasis stage (P < 0.001). Patients with reduced level of NDRG2 mRNA had a statistically significantly shorter disease-free survival and overall survival duration than patients with preserved expression of NDRG2 mRNA. In multivariate analysis, NDRG2 mRNA level was found to be an independent prognostic factor for both disease-free survival and overall survival of CRC patients. The present research provided the first evidence that decreased NDRG2 mRNA expression in primary human CRC might be a powerful, independent predictor of recurrence and outcome.

show abstract

Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma

Cited by 66 publications

References 36 publications

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study

Prediction of Colorectal Cancer Relapse and Prognosis by Tissue mRNA Levels of NDRG2

Contact Info

Product

Resources

About